Pfizer
-
In Phase 3 of clinical trials, Pfizer said it found that it’s vaccine, known as BNT162b2, was 95 percent effective in developing an immunity to COVID-19.
-
Pfizer has filed for emergency use authorization of its COVID-19 vaccine on Friday -
One of the leading COVID-19 vaccine candidates was 94 percent effective in adults older than 65, according to new clinical trial results.
-
Pfizer Inc has launched a pilot delivery program for its experimental COVID-19 vaccine in four U.S. states, as the U.S. drugmaker seeks to address distribution challenges ...
-
On Monday, Pfizer and its German partner Bio-N-Tech announced that it had preliminary results for a vaccine that’s more than 90 percent effective. It sounds like ... -
Pfizer's CEO sold shares worth $5.6 million the day the drugmaker announced that its CCP virus vaccine was more than 90 percent effective. -
1. UK hospital: 600 staff off due to COVID-19 2. Germans skeptical about Pfizer’s COVID vaccine 3. Two Belarusian diplomats expelled from UK 4. Denmark mink ...
-
A COVID-19 vaccine candidate proved strongly effective in a large phase 3 study, according to results released on Nov. 9. -
The US presidential election is having an impact on Chinese stocks. It spells both good and bad news for the communist regime.
-
Pfizer Inc received informal requests relating to its operations in China from the U.S. Department of Justice and the U.S. Securities and Exchange Commission
-
President Donald Trump is set to deliver remarks and sign a series of executive orders on lowering drug prices at 3.00 pm EDT (1900 GMT) on Friday, ...
-
WASHINGTON—The Trump administration will pay Pfizer nearly $2 billion for a December delivery of 100 million doses of a COVID-19 vaccine the pharmaceutical company is developing, ...
-
Pfizer to Buy Array BioPharma in Deal Worth $11.4 Billion
MOST VIEWED STORIES
